Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H14F3N3O3S |
Molecular Weight | 397.372 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(F)C=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(N)(=O)=O)C(F)F
InChI
InChIKey=WAZQAZKAZLXFMK-UHFFFAOYSA-N
InChI=1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)
DescriptionSources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/DrugLabels/UCM050385.pdfCurator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/21985349
Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/DrugLabels/UCM050385.pdf
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/21985349
Deracoxib (trade name Deramaxx, Novartis) is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine for the control of postoperative pain and inflammation associated with orthopedic and dental surgery and for the control of pain and inflammation associated with osteoarthritis in dogs. Data indicate that deracoxib inhibits the production of PGE1 and 6-keto PGF1 by its inhibitory effects on prostaglandin biosynthesis. Deracoxib was shown to have antitumor effect against transitional cell carcinoma of the urinary bladder.
Originator
Sources: http://www.uspto.gov/sites/default/files/web/offices/pac/dapp/opla/term/certs/5521207.pdf
Curator's Comment: Deramaxx was developed by Novartis for dogs but was discovered by G.D. Searle
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Osteosarcoma cell growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/16334957 |
150.0 µM [IC50] | ||
Target ID: O19183 Gene ID: 791253.0 Gene Symbol: PTGS2 Target Organism: Equus caballus (Horse) Sources: http://www.ncbi.nlm.nih.gov/pubmed/21219338 |
0.39 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | DERAMAXX (deracoxib) Approved UseOsteoarthritis pain and inflammation Launch Date2002 |
|||
Palliative | DERAMAXX (deracoxib) Approved UseFor postoperative orthopedic pain and inflammation Launch Date2002 |
|||
Palliative | DERAMAXX (deracoxib) Approved UseFor postoperative dental pain and inflammation Launch Date2002 |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. | 2002 Winter |
|
In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. | 2004 Apr |
|
Effects of cyclooxygenase inhibitors flunixin and deracoxib on permeability of ischaemic-injured equine jejunum. | 2005 Jan |
|
In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. | 2005 May |
|
Determination of deracoxib in feline plasma samples using high performance liquid chromatography. | 2005 May 5 |
|
Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. | 2005 Nov |
|
Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003). | 2005 Oct 1 |
|
Nonsteroidal antiinflammatory drugs: a review. | 2005 Sep-Oct |
|
Effects of deracoxib and aspirin on serum concentrations of thyroxine, 3,5,3'-triiodothyronine, free thyroxine, and thyroid-stimulating hormone in healthy dogs. | 2006 Apr |
|
The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model. | 2006 Jan |
|
Extraskeletal osteosarcoma associated with retained surgical sponge in a dog. | 2006 Mar |
|
Disposition of deracoxib in cats after oral administration. | 2006 May-Jun |
|
Effects of deracoxib or buffered aspirin on the gastric mucosa of healthy dogs. | 2006 Nov-Dec |
|
Effect of short-term sequential administration of nonsteroidal anti-inflammatory drugs on the stomach and proximal portion of the duodenum in healthy dogs. | 2006 Oct |
|
Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature. | 2007 Jul |
|
Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs. | 2007 Mar |
|
Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs. | 2007 Spring |
|
Cyclooxygenase expression and prostanoid production in pyloric and duodenal mucosae in dogs after administration of nonsteroidal anti-inflammatory drugs. | 2008 Apr |
|
Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001-2006). | 2008 Jul 1 |
|
Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs. | 2009 Aug |
|
Effect of nonsteroidal anti-inflammatory drugs with varied cyclooxygenase-2 selectivity on cyclooxygenase protein and prostanoid concentrations in pyloric and duodenal mucosa of dogs. | 2009 Oct |
|
Use of deracoxib during intense rehabilitation exercises. | 2010 |
|
Randomised controlled clinical trial for the use of deracoxib during intense rehabilitation exercises after tibial plateau levelling osteotomy. | 2010 |
|
Spontaneous pneumothorax in a dog secondary to Dirofilaria immitis infection. | 2010 Nov |
Sample Use Guides
Osteoarthritis Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, as needed. Postoperative Orthopedic Pain and inflammation: 1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration. Postoperative Dental Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/20036014
Deracoxib was used for the treatment of Canine bone marrow derived cultured mast cells (cBMCMCs) at the concentration 1uM and incubated for 24 h to strongly inhibit PGD2 and PGE2 production.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
||
|
CFR |
21 CFR 520.538
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL28636
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
7789
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
VX29JB5XWV
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
VX29JB5XWV
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
II-36
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
169590-41-4
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
3058754
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
DERACOXIB
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
m4185
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
73032
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
100000087755
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
SUB01594MIG
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
C471996
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
758935
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
DTXSID4045975
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
356834
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB11395
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY | |||
|
C73031
Created by
admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY